Longeveron Inc. (LGVN) 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Longeveron Inc.
Reporting Period: Fiscal year ended December 31, 2025.
Business Model: Clinical-stage biotechnology company developing regenerative medicines, specifically the investigational allogeneic cellular therapy laromestrocel (Lomecel-B).
Key Indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's Disease (AD), Pediatric Dilated Cardiomyopathy (DCM), and Aging-related Frailty.
Operational Status: The company has no approved products for commercial sale. It operates a cGMP manufacturing facility in Miami, Florida, and relies on third-party CDMOs for future commercial scale. The company is currently undertaking cost-saving measures, including employee furloughs and executive compensation reductions.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $1.2 million | $2.4 million |
| Gross Profit | $0.8 million | $1.9 million |
| Net Loss | $(22.7) million | $(16.0) million |
| Accumulated Deficit | $(132.3) million | $(109.6) million |
| Cash and Cash Equivalents | $4.7 million | $19.2 million |
| Operating Cash Flow | $(18.6) million | $(13.9) million |
Note: Revenue is derived primarily from The Bahamas Registry Trial and contract manufacturing services. The company has no product sales revenue.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 50% ($1.2 million) compared to 2024, driven by lower participant demand in the Bahamas Registry Trial and reduced contract manufacturing activity.
- Increased Expenses: Operating expenses rose by 31% to $24.1 million. Research and Development (R&D) expenses increased by 48% ($3.9 million) due to higher personnel costs and Chemistry, Manufacturing, and Controls (CMC) costs related to technology transfer for BLA readiness. General and Administrative (G&A) expenses increased by 17% ($1.8 million) due to headcount increases and severance costs for the former CEO.
- Liquidity Position: Cash reserves decreased significantly from $19.2 million to $4.7 million due to operating losses and capital expenditures.
- Going Concern: The independent auditor included an "Emphasis of Matter" paragraph regarding substantial doubt about the company's ability to continue as a going concern without additional capital.
Guidance, Outlook, and Risks
Clinical Outlook:
- HLHS: The pivotal Phase 2b ELPIS II trial is fully enrolled. Top-line results are anticipated in Q3 2026. A potential Biologics License Application (BLA) filing is targeted for 2027 if results are successful.
- Alzheimer's Disease: Following a positive Type B meeting with the FDA in March 2025, the company is seeking partnerships for a proposed single, pivotal, seamless adaptive Phase 2/3 trial.
- DCM: An IND became effective in July 2025, with plans to initiate a pivotal Phase 2 registrational trial in 2027.
Capital Requirements & Financing:
- The company expects current cash plus proceeds from a March 2026 private placement ($15.9 million) to fund operations into Q4 2026.
- Additional financing is required to sustain operations beyond late 2026. The company has an At-The-Market (ATM) facility for up to $10.7 million.
Key Risks:
- Liquidity: Substantial doubt exists regarding the ability to continue as a going concern without raising additional capital.
- Regulatory: No FDA-approved allogeneic cell therapies exist for the company's target indications (Frailty, AD, HLHS), creating regulatory uncertainty.
- Stock Listing: The company received a notice from Nasdaq in September 2025 regarding failure to meet the $1.00 minimum bid price requirement. A compliance period extends to March 23, 2026.
- Third-Party Dependence: Reliance on third-party suppliers for bone marrow and future CDMOs for commercial manufacturing.
Investor Verification Checklist
- Cash Runway: Verify the closing of the second tranche of the March 2026 private placement (contingent on HLHS trial results and stock price) and the sufficiency of funds to reach Q4 2026.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement by March 23, 2026, to avoid delisting.
- ELPIS II Trial Data: Await the Q3 2026 data readout for the HLHS trial, which is the primary catalyst for potential BLA filing and commercialization partnerships.
- Cost Reduction Efficacy: Assess whether the implemented furloughs and executive pay cuts are sufficient to extend the cash runway if additional financing is delayed.
- Contract Manufacturing: Confirm the status of the "Secretome" contract manufacturing agreement, as revenue from this source has substantially decreased and is not expected to be significant in the future.